Jazz Pharmaceuticals (JAZZ) reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year.Total revenues rose 9% year over year to $1.05 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.04 billion.Shares of Jazz were up 2% in yesterday’s after-market trading session, likely due to the better-than-expected earnings.The stock fell 9.3% year to date compared ...